Cervical Cancer Screening

Cervical cancer screening is the systematic testing of women without symptoms to detect precancerous changes or early cervical cancer, so that treatment can occur before invasive disease develops. It rests on the long premalignant phase of cervical lesions caused by persistent high-risk human papillomavirus (HPV) infection, and modern programs combine cytology (the Papanicolaou test) and high-risk HPV testing to identify those who need further evaluation.

Definition

Cervical cancer screening is the application of cytology and/or high-risk HPV testing to asymptomatic individuals with a cervix in order to detect precancerous lesions and early cancer at a treatable stage.

Scope

The entry covers the rationale for screening, the principal tests (cytology and HPV-based testing), and the structure of screening recommendations as a reference and educational topic. It does not specify screening intervals or management for any individual; those are set by current guidelines and clinical judgement.

Key concepts

• High-risk human papillomavirus and persistent infection
• Premalignant phase of cervical neoplasia
• Cytology (Papanicolaou test)
• Primary HPV testing and co-testing
• Sensitivity, specificity, and screening interval
• Average-risk versus higher-risk populations

Mechanisms

Persistent infection with high-risk HPV genotypes can drive progression of cervical epithelium through precancerous changes over years before invasive cancer develops; this long detectable preclinical phase is what makes screening effective. Cytology identifies abnormal cells morphologically, while HPV testing detects the causal infection and has higher sensitivity for high-grade lesions, which is why HPV-based testing has increasingly replaced or supplemented cytology in screening programs (Mayrand et al., 2007; Fontham et al., 2020).

Clinical relevance

Screening allows detection and treatment of cervical precancer before it becomes invasive, and population programs have been associated with substantial reductions in cervical cancer incidence and mortality. This entry describes screening principles for orientation; the choice of test and interval for an individual follows current guidelines and is not determined here.

Epidemiology

Cervical cancer is one of the most common cancers among women worldwide, and its burden is concentrated where organized screening and HPV vaccination are limited; the WHO has framed elimination as a global goal supported by screening and treatment of precancer (World Health Organization, 2021).

Evidence & guidelines

Major recommendations include the U.S. Preventive Services Task Force statement (USPSTF, 2018) and the American Cancer Society 2020 update favouring primary HPV testing for average-risk individuals (Fontham et al., 2020); randomized trial evidence established the higher sensitivity of HPV testing relative to cytology (Mayrand et al., 2007). The WHO provides international screen-and-treat guidance (World Health Organization, 2021).

History

Population cervical screening began with the Papanicolaou cytology test in the mid-twentieth century, which enabled detection of precancerous lesions and contributed to large declines in cervical cancer where organized programs were established. The identification of high-risk HPV as the necessary cause of cervical cancer reframed screening around the underlying infection, leading to HPV-based testing and the integration of screening with HPV vaccination (Mayrand et al., 2007; Fontham et al., 2020).

Debates

Primary HPV testing versus cytology or co-testing

Guidelines have moved toward primary high-risk HPV testing for average-risk individuals on the basis of its greater sensitivity, while questions about optimal intervals, age to start, and specificity trade-offs continue to shape recommendations.

Key figures

• George Papanicolaou
• Harald zur Hausen

Seminal works

• mayrand-2007
• uspstf-2018
• fontham-2020

Frequently asked questions

Why is HPV testing increasingly used instead of the Pap test?

High-risk HPV testing detects the infection that causes cervical cancer and is more sensitive for high-grade precancerous lesions than cytology, which is why several guidelines now favour primary HPV testing for average-risk individuals.

Does this entry tell me how often to be screened?

No. It explains the rationale and tests as a reference; recommended starting age, test, and interval depend on current guidelines and individual risk and are decided with a clinician.